2015.HK
LI.US

Electric vehicle (EV) maker Li Auto Inc. (LI.US; 2015.HK) said on Friday it delivered 51,443 vehicles in October, up 27.3% year-on-year. The growth rate represented a slowdown from this year’s third quarter, when the company’s sales rose 45% to 152,831 vehicles, according to Li Auto’s latest quarterly results also released last week.

Li Auto said it delivered a total of 393,255 vehicles in the first 10 months of this year, up 38% year-on-year. “In October, the company achieved a significant milestone with over 1 million cumulative deliveries, becoming the first Chinese premium automotive brand to reach this landmark,” Li Auto said.

China’s new energy vehicle (NEV) market is the world’s largest, accounting for more than half of global sales thanks to strong government support. But as sales growth slows, Chinese NEV makers are increasingly looking to global markets to continue their expansion – meeting with opposition from some countries that accuse them of receiving unfair government support.

Li Auto is one of China’s few EV makers that is profitable. It reported a profit of 2.81 billion yuan ($395 million) in this year’s third quarter, roughly the same as its 2.82 billion yuan profit a year earlier. Its vehicle margin improved slightly over the period to 21.2% from 20.9%. The company’s stock was up 3.7% in late Monday morning trade in Hong Kong.

By Doug Young

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?
So-Young runs cosmetic surgery clinics

Can So-Young find new youth in bricks and mortar?

The cosmetic surgery specialist’s top line is growing as it opens new ‘light medical aesthetic’ clinics, but its bottom line is sagging as its older platform business evaporates Key Takeaways:…
CSPC delivered lower nine-month revenues and profits

CSPC feels the pain from sweeping cuts in drug prices

The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…